B-MS' Baraclude "will dominate" hep B mart
US drug major Bristol-Myers Squibb's Baraclude (entecavir) will dominate the hepatitis B virus market through 2015, according to the new report, entitled Coping with the Rise in Drug Resistance: A Hepatitis B Virus Study, from Decision Resources, which concludes that this drug outperforms current therapies in efficacy and safety.
"In clinical trials, Baraclude has proved to be more efficacious in reducing viral load, which is the key end point influencing physicians' prescribing decisions," said Kaitlyn Sullivan, associate analyst at DR. "Baraclude also more effectively reduces liver fibrosis and inflammation than the other therapies currently on the market, and the agent is less prone to viral resistance than GlaxoSmithKline's Epivir (lamivudine)," she noted.
Most therapies in the pipeline for the treatment of hepatitis B virus do not have clinical profiles that can compete with Baraclude's efficacy and safety profiles, says the report.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze